Differences in prognosis by p53 expression after neoadjuvant chemotherapy in triple-negative breast cancer

Annals of Surgical Treatment and Research
Soo Youn BaeSeung Pil Jung

Abstract

Our previous studies suggested that p53-positive triple-negative breast cancer (TNBC) should be more sensitive to chemotherapy than p53-negative TNBC. The aim of this study was to determine whether p53 expression in TNBC could predict response to neoadjuvant chemotherapy and the resulting prognosis. From January 2009 to December 2017, TNBC patients who underwent neoadjuvant chemotherapy were reviewed, including a total of 31 TNBC patients who had clinical lymph node metastasis. The status of p53 expression in patients before and after chemotherapy was evaluated. Two patients (22.2%, 2 of 9) achieved pCR in p53(+) TNBC and 4 patients (50%, 5 of 10) achieved pCR in p53(-) TNBC. There was no correlation between pCR rate and p53 expression (P = 0.350). Based on prechemotherapy p53 expression, there was no significant difference in disease-free survival (DFS) between p53(+) TNBC and p53(-) TNBC (P = 0.335). However, after chemotherapy, p53(+) TNBC had shown higher DFS than p53(-) TBNC (P = 0.099). Based on prechemotherapy p53 expression, p53(+) TNBC had better overall survival (OS) than p53(-) TNBC, but the difference was not statistically significant (P = 0.082). After chemotherapy, p53(+) TNBC showed significantly better OS than p...Continue Reading

References

Aug 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rebecca DentSteven A Narod
Feb 6, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Cornelia LiedtkeLajos Pusztai
Dec 3, 2008·International Journal of Cancer. Journal International Du Cancer·Mariana VarnaPhilippe Bertheau
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
Nov 12, 2010·The New England Journal of Medicine·William D FoulkesJorge S Reis-Filho
Jun 23, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jonathan F LaraUNKNOWN Cancer and Leukemia Group B
Apr 18, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gunter von MinckwitzSibylle Loibl
Sep 25, 2012·Nature·UNKNOWN Cancer Genome Atlas Network
Oct 4, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G von Minckwitz, M Martin
Oct 5, 2015·Breast Cancer Research : BCR·Esther H LipsUNKNOWN Center for Personalized Cancer Treatment
May 12, 2018·The Kaohsiung Journal of Medical Sciences·Dong Hui ChoSeung Pil Jung
Aug 23, 2018·Breast Cancer Research and Treatment·Soo Youn BaeSeung Pil Jung
Dec 12, 2018·The Kaohsiung Journal of Medical Sciences·Soo Youn BaeSeok Jin Nam

❮ Previous
Next ❯

Software Mentioned

GeparSixto
SPSS Statistics

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.